Search Results

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity.

AnaptysBio, Inc. announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab in patients with generalized pustular psoriasis, a severe orphan disease that is potentially life-threatening if left untreated.

Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini.

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02).

Disc Medicine, Inc. announced that its previously-announced merger with Gemini Therapeutics, Inc. closed on December 29, 2022, following the approval of Gemini shareholders.

Sight Sciences, Inc. announced the acceptance for publication in Clinical Ophthalmology of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI® Surgical System technology.

Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114).

Orthofix Medical Inc., a leading global spine and orthopedics company, announced the full U.S. commercial launch and successful completion of the first cases with the Galaxy Fixation Gemini™ system.